Condition: Knee Osteoarthritis · Sponsor: Guangdong Hongzhi Health Technology
The goal of this clinical trial is to evaluate the effectiveness and safety of an autologous platelet-rich concentrated growth factor (CGF) preparation kit for the treatment of knee osteoarthritis in patients diagnosed with this condition. The main question it aims to answer is: Can the CGF preparation kit effectively improve symptoms and reduce pain in patients with knee osteoarthritis compared to a control intervention? Researchers will compare the CGF treatment group to a control group using platelet-rich plasma (PRP) to see if the CGF intervention results in greater improvements in knee function and pain relief. Participants will: Undergo three intra-articular injections of CGF or PRP into the knee joint at weekly intervals. Complete assessments including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Visual Analog Scale (VAS) for pain at specified intervals. Be monitored for safety and potential adverse events throughout the study period. Study design: Prospective, multicenter, single-blind, randomized controlled, non-inferiority clinical trial. Sample size: 104 cases, with 52 cases in the experimental group and 52 cases in the control group.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Nanfang Hospital, | Guangzhou, Guangdong, China | — |
| Shantou Central Hospital | Shantou, Guangdong, China | — |
| The Third Affiliated Hospital,Sun Yat-Sen University. | Guangdong, Guangzhou, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.